Evidence map›Paper›PMID 20371393›Full record

ReviewThe Journal of allergy and clinical immunology2010

B-cell function in severe combined immunodeficiency after stem cell or gene therapy: a review.

Rebecca H Buckley

Abstract readReview
In one paragraph

Review in The Journal of allergy and clinical immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Tailored therapies for primary immunodeficiencies.Acta bio-medica : Atenei Parmensis · 2021
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Update on Janus kinase antagonists in inflammatory bowel disease.Gastroenterology clinics of North America · 2014
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Rebecca H BuckleyDepartments of Pediatrics and Immunology, Duke University Medical Center, Durham, NC, USA. buckL003@mc.duke.edu

Funding

MECHANISMS OF ALLOGENEIC STEM CELL EDUCATION IN SCIDR01AI047605 · NIAID · DUKE UNIVERSITY · PI BUCKLEY, REBECCA H · 1999 to 2010
$3.0M
DEVELOPMENT AND PERSISTENCE OF IMMUNITY IN SCID CHIMERASR01AI042951 · NIAID · DUKE UNIVERSITY · PI BUCKLEY, REBECCA H · 1999 to 2008
$2.7M
NIAID NIH HHS R01 AI042951NIAID NIH HHS R01 AI047605
6 · The paper itself

Abstract

Although bone marrow transplantation has resulted in life-saving T-cell reconstitution in infants with severe combined immunodeficiency (SCID), correction of B-cell function has been more problematic. This review examines B-cell reconstitution results presented in 19 reports from the United States and Europe on posttransplantation immune reconstitution in patients with SCID over the past 2 decades. The analysis considered whether pretransplantation conditioning regimens were used, the overall survival rate, the percentage with donor B-cell chimerism, the percentage with B-cell function, and the percentage of survivors requiring immunoglobulin replacement. The survival rates were higher at those centers that did not use pretransplantation conditioning or posttransplantation graft-versus-host disease prophylaxis. The percentage of survivors with B-cell chimerism, function, or both was higher and the percentage requiring immunoglobulin replacement was lower at those centers that used pretransplantation conditioning. However, there were substantial numbers of patients requiring immunoglobulin replacement at all centers. Thus pretransplantation conditioning does not guarantee that B-cell function will develop. Because most infants with SCID either present with serious infections or are given diagnoses as newborns, one must decide whether there is justification for using agents that compromise innate immunity and have intrinsic toxicities to gain B-cell immune reconstitution.

Indexed as

Genetic TherapyStem Cell TransplantationB-LymphocytesClinical Trials as TopicEuropeFemaleHumansInfantInfant, NewbornMaleMulticenter Studies as TopicSevere Combined ImmunodeficiencySurvival RateTreatment OutcomeUnited States

Identifiers

PMID20371393
PMCPMC2857969

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.